Skip to Content
MIT News: 77 Mass Ave

A new angle on immunotherapy

Cancer cells injured by chemotherapy can be harnessed to unleash the immune system against tumors in mice.

December 17, 2021
cancer cells
Wikimedia Commons

Immunotherapy offers the promise of stimulating the body’s immune system to destroy tumor cells, but it only works for a handful of cancers. MIT researchers have now discovered a novel technique that they hope could enable it to target more types.

The surprising key to the approach is using chemotherapy to injure cancer cells without killing them. Led by professors Michael Yaffe and Darrell Irvine, the researchers remove tumor cells from the body, treat them with existing drugs, and then place them back in the tumor. When delivered along with drugs that activate the immune system’s T cells, these injured cancer cells appear to act as a distress signal that spurs the T cells into action against the tumors. Chemotherapy drugs that cause DNA damage are especially well suited for this type of treatment.

In 40% of mice with melanoma and breast tumors, the treatment completely eliminated the tumors. And when the researchers injected cancer cells into these same mice several months later, their T cells recognized them and destroyed them before they could form new tumors.

“When you create cells that have DNA damage but are not killed, under certain conditions those live, injured cells can send a signal that awakens the immune system,” says Yaffe. He hopes to test the approach in patients whose cancers have not responded to other immunotherapy.

Keep Reading

Most Popular

The inside story of how ChatGPT was built from the people who made it

Exclusive conversations that take us behind the scenes of a cultural phenomenon.

ChatGPT is about to revolutionize the economy. We need to decide what that looks like.

New large language models will transform many jobs. Whether they will lead to widespread prosperity or not is up to us.

Sam Altman invested $180 million into a company trying to delay death

Can anti-aging breakthroughs add 10 healthy years to the human life span? The CEO of OpenAI is paying to find out.

GPT-4 is bigger and better than ChatGPT—but OpenAI won’t say why

We got a first look at the much-anticipated big new language model from OpenAI. But this time how it works is even more deeply under wraps.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.